Dapirolizumab pegol clinical trials
Also written CDP7657.
How each study uses dapirolizumab pegol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dapirolizumab pegol studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
UCB Biopharma SRL (3) · UCB Pharma (2) · Biogen (1) · UCB Biopharma S.P.R.L. (1)
Studies
Open first, then newest update. How each study uses dapirolizumab pegol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusRecruitingPhase 3UCB Biopharma SRLNCT06617325Written as DZP
- A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus ErythematosusEnrolling by invitationPhase 3UCB Biopharma SRLNCT04976322Written as Dapirolizumab pegol
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusCompletedPhase 3UCB Biopharma SRLNCT04294667Written as DZP
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian ParticipantsCompletedPhase 1BiogenNCT04571424Written as BIIB133 (Dapirolizumab pegol)
- A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus ErythematosusCompletedPhase 2UCB Biopharma S.P.R.L.NCT02804763Written as Dapirolizumab pegol (DZP)
- Safety Study of CDP7657 in Patients With Systemic Lupus ErythematosusCompletedPhase 1UCB PharmaNCT01764594Written as CDP7657
- Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)CompletedPhase 1UCB PharmaNCT01093911Written as CDP7657
Codes
What other systems call dapirolizumab pegol · ClinicalTrials.gg INT000464
- MeSH (NLM) C000607972dapirolizumab pegolOne source ClinicalTrials.gov
- UNII (FDA) N4606MB5HMDAPIROLIZUMAB PEGOLConfirmed FDA, Wikidata
- Wikidata Q123906110dapirolizumab pegolConfirmed FDA, Wikidata
- NCI Thesaurus C174737Dapirolizumab PegolOne source FDA
- DrugBank DB16131One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000607972 | dapirolizumab pegol | One source ClinicalTrials.gov |
| UNII (FDA) | N4606MB5HM | DAPIROLIZUMAB PEGOL | Confirmed FDA, Wikidata |
| Wikidata | Q123906110 | dapirolizumab pegol | Confirmed FDA, Wikidata |
| NCI Thesaurus | C174737 | Dapirolizumab Pegol | One source FDA |
| DrugBank | DB16131 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.